GI
REGN icon

GLG Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

GLG Inc’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		$4.21M Hold
15,291
– – 0.11% 236
2013
Q3 		$4.78M Buy
+15,291
New +$4.02M 0.09% 252

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GLG Inc's REGN Position: Q4 2013 in Review

GLG Inc held its Regeneron Pharmaceuticals (REGN) position steady in Q4 2013 at 15,291 shares worth $4.21M. The position accounts for 0.11% of the portfolio, ranked #236.

GLG Inc first reported a position in REGN in Q3 2013 and has held it in 2 quarters since. The position peaked at $4.78M in Q3 2013. 437 funds tracked by Wall St. Rank hold REGN as of Q4 2013.

  • GLG Inc held 15,291 shares of Regeneron Pharmaceuticals worth $4.21M as of Q4 2013.
  • GLG Inc left its Regeneron Pharmaceuticals share count unchanged in Q4 2013.
  • Regeneron Pharmaceuticals made up 0.11% of GLG Inc's portfolio in Q4 2013, its #236 holding.
  • GLG Inc first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 2 quarters since.
  • GLG Inc's Regeneron Pharmaceuticals position peaked at $4.78M in Q3 2013.
  • 437 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2013.

Based on GLG Inc's 13F filing for Q4 2013, filed 14 Feb 2014.